Company: OCEA
Filing Date: 2025-04-08
Form Type: 10-K
Source: 0001641172-25-003155
Chunk: 2069

Company: Ocean Biomedical, Inc.
Filing Date: 2025-04-08
Form: 10-K
Item: Item 1A
Chunk 2069
---
 some or all of the criteria outlined above which
we use to assess potential new programs. We are agnostic as to which assets deliver success and believe this allows us to maintain focus
on those which continue to show most potential.

Our
product development and commercialization process reflects the disciplined and objective asset-centric philosophy described above. This
process has the following features:

    ●
    Evidence-based
    and science-driven decision making at each stage of translational and clinical development: For each product candidate, key milestones
    or decision points are set based on their ability to validate technical and commercial viability, and feasibility, as viewed from
    industry and regulatory lenses. We support each product candidate with the interdisciplinary expertise and resources to reach these
    key decision points. We review progress on an on-going basis and constantly re-assess whether the program warrants continued investment
    – i.e., we recognize the dynamic nature of these product candidates and we re-evaluate them based on development progress,
    risk factors, and market dynamics.

    ●
    Lean
    and agile translational development operations: Each program is managed by our centralized team of experienced product development
    leaders who enlist the support of relevant external resources including CROs, CMOs, domain experts, consultants, etc. We believe
    this approach is most cost-effective for clinical and commercial development and that it allows us to minimize overhead while giving
    us the flexibility to tap into the most relevant and current talent for each program without having to rely on large teams of permanent
    hires.

16

In
addition, our Research Review Committee, or RRC, which is expected to be comprised of Dr. Jack A. Elias (Scientific Co-founder), Dr.
Jonathan Kurtis (Scientific Co-founder), and Dr. Inderjote Kathuria (Chief Strategy Officer) will be responsible for the research, translational
and preclinical efforts leading to filing an IND and moving a product candidate into human clinical trials.

Our
Development Review Committee, or DRC, which is expected to be comprised of Dr. Jonathan Kurtis (Scientific Co-founder), and Inderjote
Kathuria (Chief Strategy Officer) will be responsible for managing all clinical development efforts, including progress monitoring, allocation
of resources, and continuous re-evaluation of a product candidate’s merits.

Both
these committees will work in collaboration with our OAC described previously to ensure that each product candidate that enters our pipeline
as well as existing ones continue to meet the criteria